DUBLIN--(BUSINESS WIRE)--The "New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030" report has been added to ResearchAndMarkets.com's offering.
With several ongoing research initiatives and the likely approval of multiple late stage clinical candidates, the market is expected to witness an accelerated growth and be worth USD 5-6 billion over the coming decade. Specifically, by 2030, close to 70% of the market is likely to be driven by drugs targeting transcription factors, followed by GPCRs (~18%).
The market, in the long term, is likely to be driven by five indications, namely pancreatic cancer (36%), colorectal cancer (14%), glioblastoma (12%), MDS (10%) and leukemia (10%). In terms of the geographical distribution, North America and the EU5 are expected to account for over 80% of the market.
Over 100 product candidates are currently under various stages of development against difficult-to-modulate cancer targets. Of these, 75% of the candidates are in preclinical / discovery stages. Amongst the drugs that are under clinical development, 2 are in phase III, 5 in phase II, 5 in phase I/II and 12 in phase I. Drugs in advanced clinical evaluation (phase II and above) are napabucasin (phase III), Rigosertib (phase III), BL-8040 (phase II), CX-01 (phase II), danvatirsen (phase II), GI-6301 (phase II) and siG12D LODER (phase II).
About 70% of the product candidates are being developed to treat solid tumors. Of these, pancreatic cancer (23%) is the most common; other popular indications include breast cancer (21%), lung cancer (19%) and colorectal cancer (16%). Further, about 30% of drugs are being developed for the treatment of hematological malignancies, such as acute myeloid leukemia, Burkitt lymphoma, myelodysplastic syndromes, non-Hodgkin lymphoma and multiple myeloma.
In order to advance the development efforts, stakeholders in the industry have forged several strategic partnerships. Over 50% of the agreements that have been signed since 2014 were related to the conduct of R&D activities. These were followed by licensing agreements (26%), clinical trial collaborations (9%), and product development (6%) and commercialization agreements (6%).
More than 80 funding instances, amounting to USD 915 million worth of capital, have taken place in order to support R&D in this space since 2014.
Close to 70 players have designed and developed novel proprietary technology platforms to advance R&D efforts.
Key Topics Covered
2. Executive Summary
4. Market Landscape
5. Company Profiles
6. Technology Landscape
7. Publication and Grant Analysis
8. Venture Funding and Investment Analysis
9. Partnership and Collaboration Analysis
10. Market Sizing and Opportunity Analysis
11. Key Insights
13. Interview Transcripts
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations
- A2A Pharmaceuticals
- AbbVie Ventures
- Astellas Pharma
- Aurigene Discovery Technologies
- Avergen Pharmaceuticals
- Baxter Healthcare
- Boston Biomedical
- Boxer Capital
- BridgeBio Pharma
- Bristol-Myers Squibb
- Heptares Therapeutics
- Indi Molecular
- Innovate UK
- Innovation Norway
- MiNA Therapeutics
- National Cancer Institute
- National Center for Regenerative Medicine
- Ohio State University
- Olivia Newton-John Cancer Research Institute
- OncoFusion Therapeutics
- Ractigen Therapeutics
- Sumitomo Dainippon Pharma
- Syndax Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/mqcg6n/new_frontiers_in?w=4